20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 9 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 4 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 4 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target is $196.6, accompanied by a high estimate of $235.00 and a low estimate of $131.00. A decline of 0.87% from the prior average price target is evident in the current average.
Interpreting Analyst Ratings: A Closer Look
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $180.00 | - |
| Jessica Fye | JP Morgan | Raises | Overweight | $190.00 | $170.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $180.00 | - |
| Joon Lee | Truist Securities | Maintains | Buy | $200.00 | - |
| David Amsellem | Piper Sandler | Raises | Overweight | $188.00 | $171.00 |
| Ami Fadia | Needham | Maintains | Buy | $220.00 | - |
| Annabel Samimy | Stifel | Raises | Buy | $230.00 | $225.00 |
| Oren Livnat | HC Wainwright & Co. | Lowers | Buy | $200.00 | $204.00 |
| Balaji Prasad | Barclays | Lowers | Overweight | $230.00 | $235.00 |
| Ashwani Verma | UBS | Lowers | Neutral | $131.00 | $135.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $180.00 | - |
| Gregory Renza | RBC Capital | Maintains | Outperform | $195.00 | - |
| Jessica Fye | JP Morgan | Lowers | Overweight | $170.00 | $180.00 |
| Ami Fadia | Needham | Lowers | Buy | $220.00 | $225.00 |
| Balaji Prasad | Barclays | Lowers | Overweight | $235.00 | $240.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Jazz Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Jazz Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Jazz Pharmaceuticals analyst ratings.
Get to Know Jazz Pharmaceuticals Better
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Understanding the Numbers: Jazz Pharmaceuticals's Finances
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 4.1%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.83% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 1.55. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!